Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Precigen (PGEN – Research Report) on August 11 and set a price target of $7.00. The company’s shares closed last Friday at $1.54.
Burnett covers the Healthcare sector, focusing on stocks such as Disc Medicine, Mirati Therapeutics, and Repare Therapeutics. According to TipRanks, Burnett has an average return of -14.4% and a 28.36% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Precigen with a $10.00 average price target, implying a 549.35% upside from current levels. In a report released on August 10, H.C. Wainwright also maintained a Buy rating on the stock with a $6.00 price target.
See today’s best-performing stocks on TipRanks >>
PGEN market cap is currently $393.4M and has a P/E ratio of -4.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. The product pipeline includes Isobutanol, Isobutyraldehyde, Farnesene, and Isoprene. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
Read More on PGEN:
- Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025
- Precigen reports Q2 ContOps EPS (8c), consensus (10c)
- Precigen announces agreement with FDA for Phase 1/2 study of PRGN-2012
- PGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Precigen receives FDA Breakthrough Therapy Designation for PRGN-2012
